Gyros AB, a leader in the automation of miniaturized immunoassays, confirmed today that Radix BioSolutions, a US-based contract research organization specializing in custom assay development, reagent manufacturing, and a provider of assay services, will integrate a Gyrolab™ xP workstation into their immunoassay development programs. Kerry Oliver, CEO at Radix Biosolutions explained the reasoning behind the decision, “The Gyros™ platform enables us to develop immunoassays more rapidly than any other approaches currently available. At Radix we differentiate ourselves by fostering strong relationships with our customers by meeting project requirements and timelines, and always striving to exceed expectations. Our scientists provide the experience and capabilities in reagent definition and production, robust assay development and validation, and the regulatory compliance required during the development of a customer’s therapeutic. It is essential for us to leverage leading edge technology at each stage of a project in order to best fulfill the unique needs of each customer.”

Erik Walldén, CEO at Gyros, added: “We are extremely pleased that Radix BioSolutions have recognized one of the key benefits of our immunoassay platform, namely rapid assay development. We also believe that their unique approach of making identified assay reagents commercially available will enable other Gyrolab xP workstation users working in GLP environments in the USA to procure quality controlled reagents from Radix for their own laboratory needs.”

About Gyros (www.gyros.com)
Gyros is the world leader in the automation of miniaturized, nanoscale immunoassays. Many major pharmaceutical companies and service providers - CMOs/CROs - have implemented multiple Gyrolab workstations to boost their drug development process and to meet increasing regulatory demands on testing. Rapid assay development and high throughput ensure increased productivity and efficiency with applications spanning the entire spectrum for immunoassays. The ease of assay transfer from process development to clinical evaluation of therapeutic proteins is unsurpassed in the industry. The system enables 21 CFR part 11 compliance and comprehensive validation support is available.
The company has over 50 employees based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe and is expanding its global reach through a network of distributors